Holen Sie sich die Stockscreener-App
1.495
7.55%
0.105
Handel nachbörslich:
1.49
-0.005
-0.33%
Schlusskurs vom Vortag:
$1.39
Offen:
$1.38
24-Stunden-Volumen:
2.48M
Relative Volume:
1.31
Marktkapitalisierung:
$172.42M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.9061
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
+7.55%
1M Leistung:
+55.23%
6M Leistung:
+61.74%
1J Leistung:
-50.98%
1-Tages-Spanne:
$1.30
$1.50
1-Wochen-Bereich:
$1.30
$1.66
52-Wochen-Spanne:
$0.6611
$3.50
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Vergleichen Sie FATE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.495 | 160.31M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Fate Therapeutics, Inc. Appoints Kamal Adawi as Chief Financial Officer, Effective October 20, 2025 - MarketScreener
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer - GlobeNewswire
Why Fate Therapeutics Inc. stock remains a top recommendation2025 Market Sentiment & Free Community Consensus Stock Picks - newser.com
Is Fate Therapeutics Inc. stock reversal real or fake2025 Market Trends & Daily Oversold Bounce Ideas - newser.com
Automated trading signals detected on Fate Therapeutics Inc.Trade Exit Summary & Reliable Price Breakout Alerts - newser.com
Advanced analytics toolkit walkthrough for Fate Therapeutics Inc.Options Play & Community Driven Trade Alerts - newser.com
Published on: 2025-10-13 07:01:23 - newser.com
Analyzing drawdowns of Fate Therapeutics Inc. with statistical toolsBull Run & Free Long-Term Investment Growth Plans - newser.com
What technical signals suggest for Fate Therapeutics Inc. stockJuly 2025 Short Interest & AI Enhanced Execution Alerts - newser.com
What’s next for Fate Therapeutics Inc. stock priceWeekly Earnings Recap & High Win Rate Trade Alerts - newser.com
Risk vs reward if holding onto Fate Therapeutics Inc.July 2025 Review & Free Safe Capital Growth Stock Tips - newser.com
Historical volatility pattern of Fate Therapeutics Inc. visualizedEarnings Recap Summary & High Conviction Buy Zone Picks - newser.com
Real time social sentiment graph for Fate Therapeutics Inc.Trade Volume Report & Verified Entry Point Signals - newser.com
Fate Therapeutics (NASDAQ:FATE) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Fate Therapeutics, Inc. $FATE Stock Holdings Lessened by Public Employees Retirement System of Ohio - Defense World
Fate Therapeutics (NASDAQ:FATE) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Is Fate Therapeutics Inc. stock in correction or buying zoneJuly 2025 Summary & Comprehensive Market Scan Reports - newser.com
Chart based analysis of Fate Therapeutics Inc. trendsMarket Activity Report & Real-Time Market Trend Scan - newser.com
Fate Therapeutics Inc. stock daily chart insightsPortfolio Performance Report & Weekly Breakout Stock Alerts - newser.com
What analysts say about Fate Therapeutics Inc stockPrice Gap Trading Strategies & Big Returns, Small Investment – Learn How - earlytimes.in
Detecting price anomalies in Fate Therapeutics Inc. with AI2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Is Fate Therapeutics Inc. stock affected by interest rate hikes2025 Growth vs Value & Fast Gain Stock Trading Tips - newser.com
Is Fate Therapeutics Inc. stock trading at a premium valuationFed Meeting & Real-Time Buy Signal Alerts - newser.com
Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners may be pleased with recent gains after 62% loss over the past year - Yahoo Finance
Fate Therapeutics Reports New Employee Inducement Awards under Nasdaq Listing Rule 5635(4) - MarketScreener
Should you hold or exit Fate Therapeutics Inc. now2025 Market Sentiment & Reliable Intraday Trade Alerts - newser.com
Top chart patterns to watch in Fate Therapeutics Inc.July 2025 Price Swings & High Return Trade Guides - newser.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics reports new employee inducement awards under Nasdaq listing rule - MarketScreener
Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 62% over the previous year - simplywall.st
Is Fate Therapeutics Inc a good long term investmentCandlestick Trading Patterns & Minimal Capital Growth Plans - earlytimes.in
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):